The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Samartcev I.N.

Kirov Military Medical Academy

Zhivolupov S.A.

Kirov Military Medical Academy

Butakova J.S.

Novodvinsk Central City Hospital

Parshin M.S.

City Hospital No. 26

The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)

Authors:

Samartcev I.N., Zhivolupov S.A., Butakova J.S., Parshin M.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11): s1‑s8

DOI: 10.17116/jnevro2021121111s1

Views: 2975

Downloaded: 170

Download PDF (RU)
Contact the author
Table of contents

THE OPEN OBSERVATIONAL STUDY OF ACECLOFENAC AND VINPOCETINE EFFECTIVENESS AND TOLERABILITY IN TREATMENT OF PATIENTS WITH CHRONIC CEREBROVASCULAR DISEASE AFTER COVID-19 (AQUA STUDY)
THE OPEN OBSERVATIONAL STUDY OF ACECLOFENAC AND VINPOCETINE EFFECTIVENESS AND TOLERABILITY IN TREATMENT OF PATIENTS WITH CHRONIC CEREBROVASCULAR DISEASE AFTER COVID-19 (AQUA STUDY)

To cite this article:

Samartcev IN, Zhivolupov SA, Butakova JS, Parshin MS. The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):s1‑s8. (In Russ.)
https://doi.org/10.17116/jnevro2021121111s1

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Effi­cacy and safety of a new sele­ctive oral factor Xa inhi­bitor amidine hydrochloride for the prevention of thro­mboembolic events in hospitalized patients with COVID-19. Resu­lts of a multicenter, prospective, randomized, controlled study. Journal of Venous Diso­rders. 2024;(2):154-162
Stru­ctural-functional status of cardiovascular and respiratory systems, psychoemotional diso­rders in patients with COVID-19 at the time of hospital discharge. Russian Journal of Preventive Medi­cine. 2024;(5):60-68
Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medi­cine. 2024;(5):75-80
Life quality of universities’ students during COVID-19 pandemic. Russian Journal of Preventive Medi­cine. 2024;(5):92-96
Features of olfa­ctory impairment connected with trigeminal nerve system. Russian Bulletin of Otorhinolaryngology. 2024;(2):33-39
Pulmonary high-frequency percussion ventilation in a patient with an extremely severe course of a new coro­navirus infe­ction. Russian Journal of Anesthesiology and Reanimatology. 2024;(3):81-86
Effi­cacy and Safety of a New Sele­ctive Oral Factor Xa Inhi­bitor Amidine Hydrochloride for Prevention of Thro­mboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study. Journal of Venous Diso­rders. 2024;(2):154-162
A rare variant of thro­mbosis following a novel coro­navirus infe­ction. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):329-334
Case of left ventricular wall aneurysm mani­festation in patient with Marfan syndrome after SARS-CoV-2 re-infection. Russian Journal of Preventive Medi­cine. 2024;(6):88-90
Neurological complications in patients unde­rwent COVID-19. Russian Journal of Preventive Medi­cine. 2024;(6):98-104

ABSTRACT

OBJECTIVE

To estimate the frequency of long-COVID in patients with chronic cerebrovascular disease, to identify the risk factors for the development of this condition and to analyze effectiveness and tolerability of Vinpocetine and Aertal in treatment of this disease.

MATERIAL AND METHODS

The study included 97 patients (64.5±5.2 years), among which 42 were diagnosed with long-COVID. The effectiveness of treatment was analyzed with NRS-P, Post-COVID-19 Functional Status (PCFS), Global Rating of Change Scale (GROC).

RESULTS

Predictors of long-COVID was female gender (p=0.022), severe COVID-19 (p=0.035), comorbidities: cardiovascular diseases (p=0.032), endocrinopathies (p=0.041), affective disorders (p=0.021). Significant changes in the functional status of patients were recorded after 20 days of treatment (PCFS), in pain after 10 days (NRS-P). The most pronounced clinical effect (PCFS) was obtained after 1 mth of therapy with vinpocetine and 20 days with aceclofenac (NRS-P). After 30 days 25/59.5% of patients noted a «pronounced» improvement in their own well-being (GROC) without the development of significant side effects.

CONCLUSIONS

43.3% of patients with chronic cerebrovascular disease and certain predictors develop long-COVID. Aceclofenac and vinpocetine are effective in relieving a number of symptoms of long-COVID, which requires further study.

Keywords:

chronic cerebrovascular disease
COVID-19
long-COVID
aceclofenac
vinpocetine

Authors:

Samartcev I.N.

Kirov Military Medical Academy

Zhivolupov S.A.

Kirov Military Medical Academy

Butakova J.S.

Novodvinsk Central City Hospital

Parshin M.S.

City Hospital No. 26

Received:

20.09.2021

Accepted:

18.10.2021

List of references:

  1. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015-1018. https://doi.org/10.1016/S0140-6736(20)30673-5
  2. Piroth L, Cottenet J, Mariet A, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020; 9(3):251-259.  https://doi.org/10.1016/S2213-2600(20)30527-0
  3. Rubin R. As their numbers grow, COVID-19 «Long Haulers» stump experts. JAMA. 2020;10(3)38-42.  https://doi.org/10.1001/jama.2020.17709
  4. Korompoki E, Gavriatopoulou M, Hicklen R, et al. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J Infect. 2021;83(1):1-16.  https://doi.org/10.1016/j.jinf.2021.05.004
  5. Carfi A, Bernabei R, Landi F, Gemelli T. Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605.  https://doi.org/10.1001/jama.2020.12603
  6. Graham E, Clark J, Orban Z, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 «long haulers». Ann Clin Transl Neurol. 2021;8(5):1073-1085. https://doi.org/10.1002/acn3.51350
  7. Klok F, Boon G, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal. 2020;56:200-204.  https://doi.org/10.1183/13993003.01494-2020
  8. Jensen M, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117-126.  https://doi.org/10.1016/0304-3959(86)90228-9
  9. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1998;10:407-415.  https://doi.org/10.1016/0197-2456(89)90005-6
  10. Yunkerov VI, Grigor’ev SG. Matematiko-statisticheskaya obrabotka dannykh meditsinskikh issledovanii. SPb.: VMedA; 2005. (In Russ.).
  11. Siegler J, Cardona P, Arenillas J, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 Multinational Registry. Int J Stroke. 2020;67:786-792.  https://doi.org/10.1177/1747493020959216
  12. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2020;56:7:132-130.  https://doi.org/10.1016/S0140-6736(20)32656-8
  13. Ellul M, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767-783.  https://doi.org/10.1016/s1474-4422(20)30221-0
  14. Miners S, Kehoe P, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimer’s Res Ther. 2020;12(1):34-39.  https://doi.org/10.1186/s13195-020-00744-w
  15. Wu Y, Xu X, Yang L, et al. Nervous system damage after COVID-19 infection: Presence or absence? Brain Behav Immun. 2020;87:55-61.  https://doi.org/10.1016/j.bbi.2020.04.043
  16. Troyer E, Kohn J, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39.  https://doi.org/10.1016/j.bbi.2020.04.027
  17. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients; An MRI-based 3-month follow-up study. E Clinical Medicine. 2020;25:45-49.  https://doi.org/10.1016/j.eclinm.2020.100484
  18. Liu P, Lee S, Knoll J, et al. Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis. Cell Death Differ. 2017;24(4):672-682.  https://doi.org/10.1038/cdd.2016.165
  19. Bidell M, Lodise T. Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk? Pharmacotherapy. 2016;36(6):679-693.  https://doi.org/10.1002/phar.1761
  20. Poyraz B, Poyraz C, Qlgun Y, et al. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2020;295:113-124.  https://doi.org/10.1016/j.psychres.2020.113604
  21. Townsend L, Dyer A, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. https://doi.org/10.1371/journal.pone.0240784
  22. Liu N, Zhang F, Wei C, et al. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter. Psychiatry Res. 2020;287:112921. https://doi.org/10.1016/j.psychres.2020.112921
  23. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021;53(1):151-171.  https://doi.org/10.1111/ejn.14720
  24. Guessoum S, Lachal J, Radjack R, et al. Adolescent psychiatric disorders during the COVID-19 pandemic and lockdown. Psychiatry Res. 2020;291:113264. https://doi.org/10.1016/j.psychres.2020.113264
  25. Sudre C, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631.  https://doi.org/10.1038/s41591-021-01292-y
  26. Taboada M, Carinena A, Moreno E, et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2020;82(4):31-33.  https://doi.org/10.1016/j.jinf.2020.12.022
  27. Barker-Davies R, O’Sullivan O, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54(16):949-959.  https://doi.org/10.1136/bjsports-2020-102596
  28. Kuzuya F. Effects of vinpocetine on platelet aggregability and erythrocyte deformability. Ther Hung. 1985;33(1):22-34. 
  29. Bautista Niño PK, Durik M, Danser A. Effects of vinpocetine on platelet aggregability and erythrocyte deformability Phosphodiesterase 1 regulation is a key mechanism in vascular aging. Clin Sci. 2015;129:1061-1075. https://doi.org/10.1042/CS20140753
  30. Samartsev IN, Zhivolupov SA, Butakova YuS, et al. Efficiency of long-term vinpocetine administration in the treatment of dizziness and associated statodynamic disorders in patients with chronic cerebrovascular insufficiency (EDELWEISS study). Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):36-47. (In Russ.). https://doi.org/10.14412/2074-2711-2019-1-36-47

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.